Get Premium to unlock powerful stock data
Gracell Biotechnologies Inc logo

Gracell Biotechnologies Inc

$ 3.07 -0.45 (-12.78%) 08:08 PM EST
P/E:
At Loss
P/B:
0.63
Market Cap:
$ 212.63M
Enterprise V:
$ 237.97M
Volume:
115.39K
Avg Vol (2M):
223.87K
Volume:
115.39K
Market Cap $:
212.63M
PE Ratio:
At Loss
Avg Vol (2-Month):
223.87K
Enterprise Value $:
237.97M
PB Ratio:
0.63
GF Score:
Year:
EMBED
To
10Y: -%
Above Low: +NaN%
Below High: NaN%

Business Description

Gracell Biotechnologies Inc
218 Sangtian Street, Building 12, Block B, Phase II, Biobay Industrial Park, Suzhou Industrial Park, Suzhou, CHN, 215123
Compare
Compare
Traded in other countries / regions
GRCL.USA
Description
Gracell Biotechnologies Inc is a clinical-stage biopharmaceutical company focused on developing and discovering cell and gene therapies to address and fulfill unmet medical needs in the treatment of cancer. The company aims to disrupt conventional approaches to CAR-T cell therapies with our proprietary technology platforms-FasTCAR and TruUCAR.
Name Current Vs Industry Vs History
Cash-To-Debt 11.81
Equity-to-Asset 0.89
Debt-to-Equity 0.09
Debt-to-EBITDA -0.35
Piotroski F-Score 6/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 3.61
Distress
Grey
Safe
Beneish M-Score 0
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Growth Rank

Name Current Vs Industry Vs History
3-Year EBITDA Growth Rate -29.6
3-Year EPS without NRI Growth Rate -55.7
3-Year FCF Growth Rate -17.1

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 39.79
9-Day RSI 51.22
14-Day RSI 54.79
6-1 Month Momentum % -73.94
12-1 Month Momentum % -88.47

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 12.15
Quick Ratio 12.15
Cash Ratio 11.81

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -50.6

Financials (Next Earnings Date:2022-08-17 Est.)

GRCL's 30-Y Financials

Guru Trades

See Details
To
EMBED
SAVE

Insider Trades

See Details
To
EMBED
SAVE

Gurus Latest Trades with NAS:GRCL

Peter Lynch Chart

Y-axis scale:
Interactive Chart
To
EMBED
SAVE
Performance
Dividend
To
EMBED
SAVE

Annualized Return %

Symbol 1 Week 1 Month 3 Months 6 Months YTD 1 Year 3 Years 5 Years 10 Years

Total Annual Return %

Symbol 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013

Executives

EMBED

Valuation Box

Year:
EMBED

Analyst Estimate

Key Statistics

Name Value
Revenue (TTM) (Mil $) 0.057
EPS (TTM) ($) -1.453
Beta 0
Volatility % 73.68
14-Day RSI 54.79
14-Day ATR ($) 0.345926
20-Day SMA ($) 2.8655
12-1 Month Momentum % -88.47
52-Week Range ($) 1.68 - 18.45
Shares Outstanding (Mil) 67.6

Piotroski F-Score Details

Component Result
Piotroski F-Score 6
Positive ROA
Positive CFROA
Higher ROA yoy
CFROA > ROA
Lower Leverage yoy
Higher Current Ratio yoy
Less Shares Outstanding yoy
Higher Gross Margin yoy
Higher Asset Turnover yoy

Gracell Biotechnologies Inc Filings

Document Form Filing Date
No Filing Data

Headlines

See More